Primary bladder mucinous adenocarcinoma is a rare genitourinary cancer. Here, we present the case of a 75-year-old woman where pathological and imaging findings led to the diagnosis of primary bladder mucinous adenocarcinoma. She underwent treatment with paclitaxel-ifosfamide-cisplatin (TIP). After two cycles of TIP therapy, FoundationOne CDx, a comprehensive genomic profiling test, was performed, revealing variants in , , , and . These genomic profiling test results may lead to the development of novel therapeutic agents for primary bladder mucinous adenocarcinoma.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11629251 | PMC |
http://dx.doi.org/10.1016/j.eucr.2024.102892 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!